Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
		THE CURRENT TIME at LC Labs is:

P-6040 Pimecrolimus, >98%

[Elidel] [SDZ-ASM-981]

M.W. 810.47

C43H68ClNO11

[137071-32-0]

M.I. 14:  7429

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO and ethanol, up to about 25 mg/mL.  Disposal:  A

View the MSDS for this product

• Pimecrolimus, a rapamycin (sirolimus) derivative, is a cell-selective inhibitor of inflammatory cytokines developed for the treatment of inflammatory skin diseases, such as allergic contact dermatitis, atopic dermatitis, plaque-type psoriasis, and irritant contact dermatitis.  It reduces the production of inflammatory cytokines in T cells and mast cells and inhibits the release of preformed inflammatory mediators from mast cells.  Stuetz, A., et al.  "Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity."  Semin. Cutan. Med. Surg. 20:  233-241 (2001).

• In 13 of 26 (50%) lesions of vitiligo, repigmentation was noted after a 6 month treatment of 1% pimecrolimus with a median percentage of repigmentation of 72.9% (interquartile range: 30.5-98.3%).  Total affected body surface area and duration of vitiligo tended to be inversely correlated with the success rate of treatment.  Boone, B., et al.  "Topical pimecrolimus in the treatment of vitiligo."  Eur. J. Dermatol. 17:  55-61 (2007).

• Pimecrolimus is active against mild to moderate atopic dermatitis in adults and children aged ≥ 2 years. Pimecrolimus improved the signs and symptoms of atopic dermatitis and postponed time to a major flare.  Hebert, A.A. "Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis."  Clin. Ther. 28:  1972-1982 (2006).

• Pimecrolimus is the active ingredient in the drug sold under the trade name Elidel®.  This drug is an immunomodulating agent used in the treatment of atopic dermatitis (eczema).  It is currently available as a topical cream.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Section 68B of the Patents Act of 1953 in New Zealand; (vi) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (vii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.